Concurrent delivery of dexamethasone and VEGF for localized inflammation control and angiogenesis

Journal of Controlled Release

Volumn 117, Issue 1, 2007, Pages 68-79

  Patil, Siddhesh D ^a   Papadmitrakopoulos, Fotios ^a   Burgess, Diane J ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Controlled release; Hydrogel; Microspheres; Neovascularization; Vascular endothelial growth factor

Indexed keywords

BIOMEDICAL EQUIPMENT; DRUG PRODUCTS; DRUG THERAPY; GROWTH KINETICS; HYDROGELS;

CONTROLLED RELEASE; MICROSPHERES; NEOVASCULARIZATION; VASCULAR ENDOTHELIAL GROWTH FACTORS;

DRUG DOSAGE;

DEXAMETHASONE; POLYGLACTIN; POLYVINYL ALCOHOL; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; COMPOSITE GRAFT; COMPOSITE MATERIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ELUTION; FIBROSIS; HISTOPATHOLOGY; INFLAMMATION; MEDICAL INSTRUMENTATION; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; RAT; VASCULARIZATION;

EID: 33846489090     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2006.10.013     Document Type: Article

References (59)

1. Moses J.W., Kipshidze N., and Leon M.B. Perspectives of drug-eluting stents: the next revolution. Am. J. Cardiovasc. Drugs 2 (2002) 163-172
2. Klonoff D.C. Technological advances in the treatment of diabetes mellitus: better bioengineering begets benefits in glucose measurement, the artificial pancreas, and insulin delivery. Pediatr. Endocrinol. Rev. 1 (2003) 94-100
3. Kizilel S., Garfinkel M., and Opara E. The bioartificial pancreas: progress and challenges. Diabetes Technol. Ther. 7 (2005) 968-985
4. Loisance D. Cardiac assist devices: present status and future opportunities. Expert Rev. Med. Devices 1 (2004) 43-48
5. Jones D.L., Westby M.D., Greidanus N., Johanson N.A., Krebs D.E., Robbins L., Rooks D.S., and Brander V. Update on hip and knee arthroplasty: current state of evidence. Arthritis Rheum. 53 (Oct 15 2005) 772-780
6. Catargi B. Current status and future of implantable insulin pumps for the treatment of diabetes. Expert Rev. Med. Devices 1 (2004) 181-185
7. Kissinger P.T. Biosensors-a perspective. Biosens. Bioelectron. 20 (2005) 2512-2516
8. W.G., Aranda Jr. J.M., Schofield R.S., Handberg E.M., Hill J.A., Curtis A.B., Sears S.F., Goff J.S., Pauly D.F., and Conti J.B. Management of heart failure after cardiac resynchronization therapy: integrating advanced heart failure treatment with optimal device function. J. Am. Coll. Cardiol. 46 (2005) 2193-2198
9. Wilson G.S., Zhang Y., Reach G., Moatti-Sirat D., Poitout V., Thevenot D.R., Lemonnier F., and Klein J.C. Progress toward the development of an implantable sensor for glucose. Clin. Chem. 38 (1992) 1613-1617
10. Pickup J.C., Hussain F., Evans N.D., and Sachedina N. In vivo glucose monitoring: the clinical reality and the promise. Biosens. Bioelectron. 20 (2005) 1897-1902
11. Hover C.G., Stedeford T., and Vigneulle R.M. The development of minimally invasive continuous Metabolic Monitoring Technologies in the U.S. Army TMM Research Program. Diabetes Technol. Ther. 7 (2005) 213-224
12. Pickup J.C., Claremont D.J., and Shaw G.W. Responses and calibration of amperometric glucose sensors implanted in the subcutaneous tissue of man. Acta Diabetol. 30 (1993) 143-148
13. Shaw G.W., Claremont D.J., and Pickup J.C. In vitro testing of a simply constructed, highly stable glucose sensor suitable for implantation in diabetic patients. Biosens. Bioelectron. 6 (1991) 401-406
14. Daniloff G.Y. Continuous glucose monitoring: long-term implantable sensor approach. Diabetes Technol. Ther. 1 (1999) 261-266
15. Bode B., Gross K., Rikalo N., Schwartz S., Wahl T., Page C., Gross T., and Mastrototaro J. Alarms based on real-time sensor glucose values alert patients to hypo- and hyperglycemia: the guardian continuous monitoring system. Diabetes Technol. Ther. 6 (2004) 105-113
16. Gilligan B.C., Shults M., Rhodes R.K., Jacobs P.G., Brauker J.H., Pintar T.J., and Updike S.J. Feasibility of continuous long-term glucose monitoring from a subcutaneous glucose sensor in humans. Diabetes Technol. Ther. 6 (2004) 378-386
17. Updike S.J., Shults M.C., Gilligan B.J., and Rhodes R.K. A subcutaneous glucose sensor with improved longevity, dynamic range, and stability of calibration. Diabetes Care 23 (2000) 208-214
18. Moatti-Sirat D., Capron F., Poitout V., Reach G., Bindra D.S., Zhang Y., Wilson G.S., and Thevenot D.R. Towards continuous glucose monitoring: in vivo evaluation of a miniaturized glucose sensor implanted for several days in rat subcutaneous tissue. Diabetologia 35 (1992) 224-230
19. Gaspardone A., and Versaci F. Coronary stenting and inflammation. Am. J. Cardiol. 96 (2005) 65L-70L
20. Patil S.D., Papadimitrakopoulos F., and Burgess D.J. Dexamethasone-loaded poly(lactic-co-glycolic) acid microspheres/poly(vinyl alcohol) hydrogel composite coatings for inflammation control. Diabetes Technol. Ther. 6 (2004) 887-897
21. Poitout V., Moatti-Sirat D., Reach G., Zhang Y., Wilson G.S., Lemonnier F., and Klein J.C. A glucose monitoring system for on line estimation in man of blood glucose concentration using a miniaturized glucose sensor implanted in the subcutaneous tissue and a wearable control unit. Diabetologia 36 (1993) 658-663
22. Versaci F., and Gaspardone A. Prevention of restenosis after stenting: the emerging role of inflammation. Coron. Artery Dis. 15 (2004) 307-311
23. Klueh U., Dorsky D.I., and Kreutzer D.L. Use of vascular endothelial cell growth factor gene transfer to enhance implantable sensor function in vivo. J. Biomed. Mater. Res., A 67 (2003) 1072-1086
24. Klueh U., Dorsky D.I., Moussy F., and Kreutzer D.L. Ex ova chick chorioallantoic membrane as a novel model for evaluation of tissue responses to biomaterials and implants. J. Biomed. Mater. Res., A 67 (2003) 838-843
25. Updike S.J., Shults M.C., Rhodes R.K., Gilligan B.J., Luebow J.O., and von Heimburg D. Enzymatic glucose sensors. Improved long-term performance in vitro and in vivo. ASAIO J. 40 (1994) 157-163
26. Kuchulakanti P., and Waksman R. Therapeutic potential of oral antiproliferative agents in the prevention of coronary restenosis. Drugs 64 (2004) 2379-2388
27. Galeska I., Kim T.K., Patil S.D., Bhardwaj U., Chatttopadhyay D., Papadimitrakopoulos F., and Burgess D.J. Controlled release of dexamethasone from PLGA microspheres embedded within polyacid-containing PVA hydrogels. AAPS J. 7 (2005) E231-E240
28. Luo J.C., Shin V.Y., Liu E.S.L., Ye Y.N., Wu W.K.K., So W.H.L., Chang F.Y., and Cho C.H. Dexamethasone delays ulcer healing by inhibition of angiogenesis in rat stomachs. Eur. J. Pharmacol. 485 (2004) 275-281
29. Koedam J.A., Smink J.J., and van Buul-Offers S.C. Glucocorticoids inhibit vascular endothelial growth factor expression in growth plate chondrocytes. Mol. Cell. Endocrinol. 197 (2002) 35-44
30. Iwai A., Fujii Y., Kawakami S., Takazawa R., Kageyama Y., Yoshida M.A., and Kihara K. Down-regulation of vascular endothelial growth factor in renal cell carcinoma cells by glucocorticoids. Mol. Cell. Endocrinol. 226 (2004) 11-17
31. Elcin Y.M., Dixit V., and Gitnick G. Extensive in vivo angiogenesis following controlled release of human vascular endothelial cell growth factor: implications for tissue engineering and wound healing. Artif. Organs 25 (2001) 558-565
32. Gu F., Amsden B., and Neufeld R. Sustained delivery of vascular endothelial growth factor with alginate beads. J. Control. Release 96 (2004) 463-472
33. Weber F.E., Eyrich G., Gratz K.W., Maly F.E., and Sailer H.F. Slow and continuous application of human recombinant bone morphogenetic protein via biodegradable poly(lactide-co-glycolide) foamspheres. Int. J. Oral Maxillofac. Surg. 31 (2002) 60-65
34. Sun Q., Chen R.R., Shen Y., Mooney D.J., Rajagopalan S., and Grossman P.M. Sustained vascular endothelial growth factor delivery enhances angiogenesis and perfusion in ischemic hind limb. Pharm. Res. 22 (2005) 1110-1116
35. Freitas S., Merkle H.P., and Gander B. Microencapsulation by solvent extraction/evaporation: reviewing the state of the art of microsphere preparation process technology. J. Control. Release 102 (2005) 313-332
36. Kim T.K., and Burgess D.J. Pharmacokinetic characterization of 14C-vascular endothelial growth factor controlled release microspheres using a rat model. J. Pharm. Pharmacol. 54 (2002) 897-905
37. Kim H.K., and Park T.G. Comparative study on sustained release of human growth hormone from semi-crystalline poly(l-lactic acid) and amorphous poly(d,l-lactic-co-glycolic acid) microspheres: morphological effect on protein release. J. Control. Release 98 (2004) 115-125
38. Cui F., Cun D., Tao A., Yang M., Shi K., Zhao M., and Guan Y. Preparation and characterization of melittin-loaded poly (dl-lactic acid) or poly (dl-lactic-co-glycolic acid) microspheres made by the double emulsion method. J. Control. Release 107 (2005) 310-319
39. Okada H. One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv. Drug Deliv. Rev. 28 (1997) 43-70
40. Shive M.S., and Anderson J.M. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 28 (1997) 5-24
41. Daugherty A.L., Cleland J.L., Duenas E.M., and Mrsny R.J. Pharmacological modulation of the tissue response to implanted polylactic-co-glycolic acid microspheres. Eur. J. Pharm. Biopharm. 44 (1997) 89-102
42. Duncan G., Jess T.J., Mohamed F., Price N.C., Kelly S.M., and van der Walle C.F. The influence of protein solubilisation, conformation and size on the burst release from poly(lactide-co-glycolide) microspheres. J. Control. Release 110 (2005) 34-48
43. King T.W., and Patrick C.W.J. Development and in vitro characterization of vascular endothelial growth factor (VEGF)-loaded poly(dl-lactic-co-glycolic acid)/poly(ethylene glycol) microspheres using a solid encapsulation/single emulsion/solvent extraction technique. J. Biomed. Mater. Res. 51 (2000) 383-390
44. Ogomi D., Serizawa T., and Akashi M. Controlled release based on the dissolution of a calcium carbonate layer deposited on hydrogels. J. Control. Release 103 (2005) 315-323
45. Zambaux M.F., Bonneaux F., Gref R., Dellacherie E., and Vigneron C. Protein C-loaded monomethoxypoly (ethylene oxide)-poly(lactic acid) nanoparticles. Int. J. Pharm. 212 (2001) 1-9
46. O'Donnell P.B., and McGinity J.W. Preparation of microspheres by the solvent evaporation technique. Adv. Drug Deliv. Rev. 28 18 (1997) 25-42
47. Sanders J.E., Bale S.D., and Neumann T. Tissue response to microfibers of different polymers: polyester, polyethylene, polylactic acid, and polyurethane. J. Biomed. Mater. Res. 62 (2002) 222-227
48. Shin H., Quinten R.P., Mikos A.G., and Jansen J.A. In vivo bone and soft tissue response to injectable, biodegradable oligo(poly(ethylene glycol) fumarate) hydrogels. Biomaterials 24 (2003) 3201-3211
49. Vance R.J., Miller D.C., Thapa A., Haberstroh K.M., and Webster T.J. Decreased fibroblast cell density on chemically degraded poly-lactic-co-glycolic acid, polyurethane, and polycaprolactone. Biomaterials 25 (2004) 2095-2103
50. Hyung P.J., and Bae Y.H. Hydrogels based on poly(ethylene oxide) and poly(tetramethylene oxide) or poly(dimethyl siloxane). III. In vivo biocompatibility and biostability. J. Biomed. Mater. Res., A 64 (2003) 309-319
51. Rofstad E.K., and Halsor E.F. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res. 60 (2000) 4932-4938
52. Appleton I., Brown N.J., Willis D., Colville-Nash P.R., Alam C., Brown J.R., and Willoughby D.A. The role of vascular endothelial growth factor in a murine chronic granulomatous tissue air pouch model of angiogenesis. J. Pathol. 180 (1996) 90-94
53. Reinders M.E., Sho M., Izawa A., Wang P., Mukhopadhyay D., Koss K.E., Geehan C.S., Luster A.D., Sayegh M.H., and Briscoe D.M. Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J. Clin. Invest. 112 (2003) 1655-1665
54. Zhao Q., Egashira K., Inoue S., Usui M., Kitamoto S., Ni W., Ishibashi M., Hiasa K.K., Ichiki T., Shibuya M., and Takeshita A. Vascular endothelial growth factor is necessary in the development of arteriosclerosis by recruiting/activating monocytes in a rat model of long-term inhibition of nitric oxide synthesis. Circulation 105 (2002) 1110-1115
55. Cui J.Z., Kimura H., Spee C., Thumann G., Hinton D.R., and Ryan S.J. Natural history of choroidal neovascularization induced by vascular endothelial growth factor in the primate. Graefes Arch. Clin. Exp. Ophthalmol. 238 (2000) 326-333
56. Peirce S.M., Price R.J., and Skalak T.C. Spatial and temporal control of angiogenesis and arterialization using focal applications of VEGF164 and Ang-1. Am. J. Physiol., Heart Circ. Physiol. 286 (2004) H918-H925
57. Youssif M., Shiina H., Urakami S., Gleason C., Nunes L., Igawa M., Enokida H., Tanagho E.A., and Dahiya R. Effect of vascular endothelial growth factor on regeneration of bladder acellular matrix graft: histologic and functional evaluation. Urology 66 (2005) 201-207
58. Zacchigna S., Papa G., Antonini A., Novati F., Moimas S., Carrer A., Arsic N., Zentilin L., Visintini V., Pascone M., and Giacca M. Improved survival of ischemic cutaneous and musculocutaneous flaps after vascular endothelial growth factor gene transfer using adeno-associated virus vectors. Am. J. Pathol. 167 (2005) 981-991
59. Pevec W.C., Ndoye A., Brinsky J.L., Wiltse S., and Cheung A.T. New blood vessels can be induced to invade ischemic skeletal muscle. J. Vasc. Surg. 24 (1996) 534-541